Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study

Lupus

Volumn 27, Issue 3, 2018, Pages 357-364

  Yelnik, C M ^a,b   Urbanski, G ^b   Drumez, E ^c   Caron, C ^b   Maillard, H ^b   Morell Dubois, S ^b   Dubucquoi, S ^a,b,d   Launay, D ^a,b,d   Hachulla, E ^a,b,d   Hatron, P Y ^a,b   Duhamel, A ^c   Lambert, M ^a,b,d  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIV LILLE   (France)

^d UNIVERSITÉ DE LILLE   (France)

Author keywords

Anticoagulant therapy; antiphospholipid antibody; antiphospholipid syndrome; relapse; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; PHOSPHOLIPID ANTIBODY;

AGED; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; LUNG SCINTISCANNING; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VEIN THROMBOSIS; ADULT; BLOOD CLOTTING; CASE CONTROL STUDY; COMPLICATION; DRUG EFFECT; IMMUNOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK FACTOR; THROMBOSIS; YOUNG ADULT;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; BLOOD COAGULATION; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS; YOUNG ADULT;

EID: 85042118964     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203317721751     Document Type: Article

References (27)

1. Cervera R, Piette JC, Font J, Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019–1027.
2. Miyakis S, Lockshin MD, Atsumi T, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.
3. Kearon C, Gent M, Hirsh J, A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901–907.
4. Rosove MH, Brewer PM. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303–308.
5. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011; 20: 206–218.
6. Zuily S, Rat AC, Regnault Impairment of quality of life in patients with antiphospholipid syndrome. Lupus 2015; 24: 1161–1168.
7. Pengo V, Ruffatti A, Legnani C, Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237–242.
8. Bertero MT, Bazzan M, Carignola R, Antiphospholipid syndrome in northwest Italy (APS Piedmont Cohort): Demographic features, risk factors, clinical and laboratory profile. Lupus 2012; 21: 806–809.
9. Cervera R, Khamashta MA, Shoenfeld Y, Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: A multicentre prospective study of 1000 patients. Ann Rheum Dis 2009; 68: 1428–1432.
10. Pengo V, Tripodi A, Reber G, Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737–1740.
11. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.
12. Turiel M, Sarzi-Puttini P, Peretti R, Thrombotic risk factors in primary antiphospholipid syndrome: A 5-year prospective study. Stroke J Cereb Circ 2005; 36: 1490–1494.
13. Bazzan M, Vaccarino A, Stella S, Thrombotic recurrences and bleeding events in APS vascular patients: A review from the literature and a comparison with the APS Piedmont Cohort. Autoimmun Rev 2013; 12: 826–831.
14. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998; 104: 332–338.
15. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton LJ, 3rd. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population-based cohort study. Arch Intern Med 2000; 160: 761–768.
16. Prandoni P, Noventa F, Ghirarduzzi A, The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92: 199–205.
17. Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: A systematic review. Blood 2013; 122: 817–824.
18. Forastiero R, Martinuzzo M, Pombo G, A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005; 3: 1231–1238.
19. Erkan D, Barbhaiya M, George D, Sammaritano L, Lockshin M. Moderate versus high-titer persistently anticardiolipin antibody positive patients: Are they clinically different and does high-titer anti-beta 2-glycoprotein-I antibody positivity offer additional predictive information? Lupus 2010; 19: 613–619.
20. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93: 1147–1152.
21. Hernández-Molina G, Espericueta-Arriola G, Cabral AR. The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome. Clin Exp Rheumatol 2013; 31: 382–388.
22. Nash MJ, Camilleri RS, Kunka S, Mackie IJ, Machin SJ, Cohen H. The anticardiolipin assay is required for sensitive screening for antiphospholipid antibodies. J Thromb Haemost 2004; 2: 1077–1081.
23. Pengo V, Ruffatti A, Del Ross T, Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J Thromb Haemost 2013; 11: 1527–1531.
24. Criado-García J, Fernández-Puebla RA, Jiménez LL, Velasco F, Santamaría M, Blanco-Molina A. Anticoagulation treatment withdrawal in primary antiphospholipid syndrome when anticardiolipin antibodies become negative [article in Spanish]. Rev Clín Esp 2008; 208: 135–137.
25. Coloma Bazán E, Donate López C, Moreno Lozano P, Cervera R, Espinosa G. Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. Immunol Res 2013; 56: 358–361.
26. Okuma H, Kitagawa Y, Yasuda T, Tokuoka K, Takagi S. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci 2009; 7: 15–18.
27. Tan BE, Thong BY, Shivananda S, Han WW, Chng HH. Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort. Lupus 2009; 18: 752–758.